Navigation Links
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Date:12/9/2008

Studies Presented at American Epilepsy Society Annual Meeting

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR(TM) (levetiracetam) extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and reporting on additional dosing schedules. The data were among five studies that were presented at the 62nd annual meeting of the American Epilepsy Society (AES) in Seattle.

Keppra XR was approved by the U.S. Food and Drug Administration in September 2008 for use as adjunctive treatment for people with partial-onset seizures who are 16 years of age and older.

"In this new meta-analysis, patients taking Keppra XR experienced fewer nervous system side effects than those taking the same dose of twice daily levetiracetam," said James Zackheim, Medical Director, CNS, UCB. "Keppra XR is the only once-daily, extended-release formulation of levetiracetam, and there is no generic alternative available."

Summary of Keppra XR Data Presented at 2008 AES Annual Meeting

Safety Profile of Levetiracetam Extended Release Compared to Immediate Release: An Indirect Comparison Using a Meta-Analytic Approach

Researchers conducted a meta-analysis of Phase III data to determine whether Keppra XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. According to the meta-analysis, patients taking Keppra XR once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily.

-- In terms of overall tolerability, 52.8% of Keppra XR patients reported any adverse event, compared with 79% of patients taking levetiracetam IR.

-- While adverse events associated with levetiracetam IR were also observed with Keppra XR, patients treated with Keppra XR once
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
3. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
4. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
5. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
6. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
10. Opportunities to Highlight Type 1 Diabetes in November
11. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, ... it has initiated a phase I clinical trial ... evaluate the safety, tolerability, and immunogenicity of INO-3106. ... which causes most aerodigestive cancers. Aerodigestive ... vocal cords, and parts of the esophagus and ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... , Sept. 22, 2014 Auxilium Pharmaceuticals, ... biopharmaceutical company, today announced that its Board of ... and conditional proposal from Endo International plc ("Endo") ... legal advisors, has unanimously determined it is not ... existing merger agreement with QLT Inc. ("QLT") and ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based practitioners, today announced that its disaster relief hotline ... experience operational, logistical or financial issues as a result ... number for all dental, medical and animal health customers ...
... Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ), announced ... the Jefferies 2011 Global Healthcare Conference on June 9, 2011 ... The live and archived webcast of the company presentation can ... Center at www.idenix.com . Please log in approximately 5-10 ...
Cached Medicine Technology:Henry Schein Disaster Relief Hotline Remains Open for Customers Affected by Devastating Storms 2Henry Schein Disaster Relief Hotline Remains Open for Customers Affected by Devastating Storms 3
(Date:9/22/2014)... out to be an old acquaintance: a certain module ... been considered an anchor protein. The researchers report their ... Essential: importing enzymes into peroxisome , Peroxisomes are ... fatty acids and cellular toxins. In order for them ... be imported into the peroxisomes first. The bulk is ...
(Date:9/22/2014)... of more than 30,000 nurses across Europe show that ... more likely to rate the standard of care delivered ... of their hospitals safety and omit necessary patient care. ... and the National Nursing Research Unit (NNRU) at King,s ... 450 hospitals across 12 European countries, was part of ...
(Date:9/22/2014)... Following 14 months of field ... Clearwater Clinical announced the general release of ... for smartphones. ClearSCOPE enables health professionals to capture ... and smartphone. , ENT and Urology specialists developed ... over the cost, encumbrance and slow innovation cycle ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... The invitation only Summit held ... 60 industry executives and thought leaders from major ... Retro Fitness, and Xsport Fitness. Also in attendance ... marketing agencies and private equity investors representing over ... , The Summit highlighted best practices for solving ...
Breaking Medicine News(10 mins):Health News:The accelerator of molecular motors 2Health News:Nurse survey shows longer working hours impact on quality of care 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... ARBOR, Mich.---Scientists have discovered a molecular assistant called Spy that ... purposes. Bacteria are widely used to manufacture proteins used ... job. Many proteins fall apart and get cut up inside ... useless tangles instead of folding properly, as they must in ...
... FL 14 February, 2011 Elsevier / MEDai, ... announced today the launch of the latest version of ... The new version will feature an expanded set of ... new predictions: ICU Admission Prediction, Length of Stay Prediction ...
... two pesticides, rotenone and paraquat, and Parkinson,s disease. People ... times more often than non-users. The study ... National Institute of Environmental Health Sciences (NIEHS), which is ... Parkinson,s Institute and Clinical Center in Sunnyvale, Calif. ...
... 11 (HealthDay News) -- The U.S. Food and Drug ... that provides three-dimensional images of the breast for cancer ... an upgrade to Massachusetts-based Hologic Inc.,s FDA-approved two-dimensional system, ... breasts. The 3-D images may help physicians more accurately ...
... , SUNDAY, Feb. 13 (HealthDay News) -- People who ... may be protecting themselves from developing Parkinson,s disease, a ... are found in a variety of foods such as ... touted as protective against some diseases because of their ...
... News) -- Hunters who use tree stands can stay safe ... a study on tree stand safety. The reminder comes ... from tree stands and four died during the recent deer-hunting ... falls in Alabama in a single year, said the state,s ...
Cached Medicine News:Health News:Quest for designer bacteria uncovers a 'Spy' 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:FDA Approves First 3D Mammogram Device 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Spate of Hunter Injuries Spurs New Call for Tree Stand Safety 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: